0001498403 2025-01-01 2025-12-31 0001498403 dei:BusinessContactMember 2025-01-01 2025-12-31 0001498403 2026-03-08 shares 20-F/A 0001498403 true FY false true 2025-12-31 --12-31 2025 false false 001-35223 BioLineRx Ltd. L3 2 HaMa’ayan Street Modi’in 7177871 IL Philip A. Serlin 972 642-9100 972 (8) 642-9101 phils@biolinerx.com 2 HaMa’ayan Street Modi’in 7177871 IL 2610814390 No No Yes Yes Non-accelerated Filer false false false International Financial Reporting Standards false This Amendment No. 1 to Form 20-F (this “Amendment”) amends the annual report on Form 20-F of BioLineRx Ltd. for the year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission on March 23, 2026 (the “Original Report”). This Amendment is being filed solely to revise the consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited (“PwC”) included in Exhibit 15.1 of the Original Report. The consent included in the Original Report referenced the incorrect date of the report of PwC. A new consent of PwC is being filed as an exhibit hereto.   As required by Rule 12b-15 under the Exchange Act, as amended, new certifications by our principal executive officer and principal financial officer are being filed as Exhibits 12.1, 12.2, 13.1 and 13.2 to this Amendment.   This Amendment does not reflect events occurring after the filing of the Original Report and does not modify or update the disclosure therein in any way except as described above or herein. No other changes have been made to the Original Report. The filing of this Amendment should not be understood to mean that any statements contained in the Original Report, as amended by this Amendment, are true or complete as of any date subsequent to the original filing date of the Original Report.